Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2023-02-02
- Lead Sponsor
- Alvotech Swiss AG
- Target Recruit Count
- 581
- Registration Number
- NCT04930042
- Locations
- 🇬🇪
Aleksandre Aladashvili Clinic, LLC, Tbilisi, Georgia
🇪🇪Tartu University Hospital, Tartu, Estonia
🇪🇪North Estonia Medical Centre, Tallin, Estonia
Pharmacokinetics, Safety and Tolerability Study of AVT04 to EU Approved and US Licensed Stelara (Ustekinumab)
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2022-05-23
- Lead Sponsor
- Alvotech Swiss AG
- Target Recruit Count
- 294
- Registration Number
- NCT04744363
- Locations
- 🇳🇿
ACS, Auckland, New Zealand
🇳🇿CCST, Christchurch, New Zealand
🇦🇺Nucleus Network, Brisbane, Australia
Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2022-05-04
- Lead Sponsor
- Alvotech Swiss AG
- Target Recruit Count
- 567
- Registration Number
- NCT04453137
- Locations
- 🇮🇸
Alvotech Swiss AG - Site 3501, Reykjavik, Iceland
🇵🇱Alvotech Swiss AG - 4808, Wrocław, Poland
🇷🇺Alvotech Swiss AG - Site 7004, Saint Petersburg, Russian Federation
Auto-injector Real Life Handling in Patients
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2022-05-05
- Lead Sponsor
- Alvotech Swiss AG
- Target Recruit Count
- 107
- Registration Number
- NCT04224194
- Locations
- 🇬🇪
Aleksandre Aladashvili Clinic LLC, Tbilisi, Georgia
🇬🇪JSC "EVEX Hospitals", Tbilisi, Georgia
🇺🇦SI D. F. Chebotarev Institute of Gerontology NAMS Ukraine, Kyiv, Ukraine
PK, Safety and Tolerability Study of AVT02 (Adalimumab) Pre-filled Syringe (PFS) vs, AVT02 Autoinjector (AI)
- First Posted Date
- 2019-06-12
- Last Posted Date
- 2022-05-04
- Lead Sponsor
- Alvotech Swiss AG
- Target Recruit Count
- 207
- Registration Number
- NCT03983876
- Locations
- 🇳🇿
Auckland Clinical Studies, Auckland, New Zealand
🇳🇿Christchurch Clinical Studies Trust Limited, Christchurch, Chistchurch, New Zealand
Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab)
- First Posted Date
- 2019-02-21
- Last Posted Date
- 2022-05-04
- Lead Sponsor
- Alvotech Swiss AG
- Target Recruit Count
- 390
- Registration Number
- NCT03849313
- Locations
- 🇦🇺
Scientia Clinical Research, Sydney, New South Wales, Australia
🇳🇿Auckland Clinical Studies, Auckland, New Zealand
🇳🇿Christchurch Clinical Studies Trust Limited, Christchurch, Chistchurch, New Zealand
Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis
- First Posted Date
- 2019-02-21
- Last Posted Date
- 2020-07-28
- Lead Sponsor
- Alvotech Swiss AG
- Target Recruit Count
- 413
- Registration Number
- NCT03849404
- Locations
- 🇵🇱
DermMedica Sp. z o.o., Wrocław, Poland
🇪🇪OU Vahlberg & Pild, Tallin, Estonia
🇪🇪Tartu University Hospital, Dermatology Clinic, Tartu, Estonia
Comparative Safety, Tolerability, Pharmacokinetic Study of AVT02 (100MG/ML) and Humira (100MG/ML) in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2018-07-09
- Last Posted Date
- 2019-01-18
- Lead Sponsor
- Alvotech Swiss AG
- Target Recruit Count
- 24
- Registration Number
- NCT03579823
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia